Company Filing History:
Years Active: 1999-2001
Title: Werner Scherbaum: Innovator in Monoclonal Antibodies
Introduction
Werner Scherbaum is a notable inventor based in Ulm, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work has implications for diabetes research and treatment.
Latest Patents
Scherbaum's latest patents include innovative methods for producing human monoclonal antibodies of the IgG isotype that specifically bind to glutamate decarboxylase. This invention focuses on human monoclonal antibodies against pancreatic islet cells, which can be obtained by immortalizing human lymphocytes from prediabetics or diabetics. The process involves treating the culture supernatant of immortalized cells with a conjugate of antibodies against human Fc and a label, followed by incubation with immobilized human pancreatic islet cells. This method allows for the identification and isolation of immortalized human cell cultures that produce antibodies against pancreatic islet cells.
Career Highlights
Throughout his career, Scherbaum has worked with prominent companies in the biotechnology sector, including Boehringer Mannheim GmbH and Roche Diagnostics GmbH. His experience in these organizations has contributed to his expertise in the field of immunology and antibody development.
Collaborations
Scherbaum has collaborated with notable colleagues such as Josef Endl and Michael Brandt. These partnerships have furthered his research and innovation in monoclonal antibodies.
Conclusion
Werner Scherbaum's contributions to the field of biotechnology, particularly in the development of monoclonal antibodies, have made a significant impact on diabetes research. His innovative patents and collaborations highlight his role as a leading inventor in this important area of medical science.